Special Correspondent

CHENNAI: Arguments on the petitions filed by Novartis AG, challenging the Constitutional validity of Section 3(d) of the Patents (Amendment) Act 2005 concluded before a Division Bench of the Madras High Court on Wednesday.

The Bench, comprising Justices R. Balasubramanian and Prabha Sridevan, however, commenced hearing on the statutory appeal of the company against the rejection of its application to patent beta crystalline form of imatinib mesylate, sold under the brand name Gleevec/Glivec.

While senior advocate P.S. Raman wound up the arguments, counsel for Cipla, Sun Pharmaceuticals and the Indian Pharmaceutical Alliance A. Ramesh Kumar, said he would file written submissions before the court.